Literature DB >> 14719072

Thymidine kinase and thymidine phosphorylase level as the main predictive parameter for sensitivity to TAS-102 in a mouse model.

Tomohiro Emura1, Fumio Nakagawa, Akio Fujioka, Hideyuki Ohshimo, Kenji Kitazato.   

Abstract

TAS-102 is a new oral anti-cancer drug preparation, composed of a 1:0.5 mixture (on a molar basis) of alpha,alpha,alpha-trifluorothymidine (FTD) and 5-chloro-6-[1-(2-iminopyrrolidinyl)methyl]-2,4(1H,3H)-pyrimidinedione hydrochloride (TPI). TAS-102 currently undergoing clinical trials, has been demonstrated to have at least two mechanisms, inhibition of TS and incorporation into DNA. We hypothesized that the thymidine metabolism enzyme may be a crucial factor that affects the antitumor activity of TAS-102. In the present study, we measured the enzyme activity of thymidine kinase (TK), thymidine phosphorylase (TP) and thymidilate synthase (TS) in human cancer xenografts to investigate the contribution of these enzymes to the sensitivity of TAS-102. Antitumor activity of TAS-102 appears to be associated with TK, tumor growth and TS. However, the most related factors in this study were the TK and TP ratio. There was a significant correlation (p=0.04) between tumor growth inhibition and this ratio. These results suggested that the activation and degradation pattern of FTD plays an important role in the efficacy of TAS-102 and that it is possible to use the TK/TP ratio to predict response to TAS-102 therapy. We also studied the influence of TPI on the capacity of exogenous dThd to reverse FTD-dependent growth inhibition. Thymidine (dThd) levels rescued the effect of FTD in vitro and significantly increased in serum after administration of TAS-102 or TPI alone but not FTD alone. This may suggest the possibility of a decrease in antitumor effect. However, our study indicated that the therapeutic index was clearly increased by FTD combined with TPI, compared with FTD alone, suggesting FTD-induced toxicity to sensitive host tissue can be selectively reversed with dThd. In conclusion, TK and TPI effects on TP play important roles in the cytotoxic action of TAS-102, and it is possible to use the TK/TP ratio to predict more precisely individual resistance or sensitivity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14719072

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  12 in total

1.  TAS-102 has a tumoricidal activity in multiple myeloma.

Authors:  Guoli Li; Huan Liu; Jin He; Zongwei Li; Zhiming Wang; Shan Zhou; Guopei Zheng; Zhimin He; Jing Yang
Journal:  Am J Cancer Res       Date:  2020-11-01       Impact factor: 5.942

2.  Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors.

Authors:  Michael J Overman; Gauri Varadhachary; Scott Kopetz; Melanie B Thomas; Masakazu Fukushima; Keizo Kuwata; Akira Mita; Robert A Wolff; Paulo M Hoff; Henry Xiong; James L Abbruzzese
Journal:  Invest New Drugs       Date:  2008-06-05       Impact factor: 3.850

Review 3.  Therapeutic potential of TAS-102 in the treatment of gastrointestinal malignancies.

Authors:  Godefridus J Peters
Journal:  Ther Adv Med Oncol       Date:  2015-11       Impact factor: 8.168

4.  Mechanism of acquired 5FU resistance and strategy for overcoming 5FU resistance focusing on 5FU metabolism in colon cancer cell lines.

Authors:  Tomonari Suetsugu; Ryutaro Mori; Manabu Futamura; Masahiro Fukada; Hideharu Tanaka; Itaru Yasufuku; Yuta Sato; Yoshinori Iwata; Takeharu Imai; Hisashi Imai; Yoshihiro Tanaka; Naoki Okumura; Nobuhisa Matsuhashi; Takao Takahashi; Kazuhiro Yoshida
Journal:  Oncol Rep       Date:  2021-03-02       Impact factor: 3.906

5.  Protective autophagy by thymidine causes resistance to rapamycin in colorectal cancer cells in vitro.

Authors:  I V Bijnsdorp; Godefridus J Peters
Journal:  Cancer Drug Resist       Date:  2021-05-24

6.  The Hollow Fibre Assay as a model for in vivo pharmacodynamics of fluoropyrimidines in colon cancer cells.

Authors:  O H Temmink; H-J Prins; E van Gelderop; G J Peters
Journal:  Br J Cancer       Date:  2006-12-19       Impact factor: 7.640

7.  Anticancer activity of a thymidine quinoxaline conjugate is modulated by cytosolic thymidine pathways.

Authors:  Qiong Wei; Haijuan Liu; Honghao Zhou; Dejun Zhang; Zhiwei Zhang; Qibing Zhou
Journal:  BMC Cancer       Date:  2015-03-21       Impact factor: 4.430

8.  Monitoring trifluridine incorporation in the peripheral blood mononuclear cells of colorectal cancer patients under trifluridine/tipiracil medication.

Authors:  Ryota Nakanishi; Hiroyuki Kitao; Mamoru Kiniwa; Yosuke Morodomi; Makoto Iimori; Junji Kurashige; Masahiko Sugiyama; Yuichiro Nakashima; Hiroshi Saeki; Eiji Oki; Yoshihiko Maehara
Journal:  Sci Rep       Date:  2017-12-05       Impact factor: 4.379

Review 9.  The dual role of thymidine phosphorylase in cancer development and chemotherapy.

Authors:  Annelies Bronckaers; Federico Gago; Jan Balzarini; Sandra Liekens
Journal:  Med Res Rev       Date:  2009-11       Impact factor: 12.944

Review 10.  Emerging combination therapies for metastatic colorectal cancer - impact of trifluridine/tipiracil.

Authors:  Jeevan M Puthiamadathil; Benjamin A Weinberg
Journal:  Cancer Manag Res       Date:  2017-10-03       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.